Convergence continues: Sanofi and Medtronic plan drug-device combo to treat diabetes

Featured Story

Convergence continues: Sanofi and Medtronic plan drug-device combo to treat diabetes

June 15, 2014 11:45 am by | 0 Comments

PARIS (Reuters) – French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes.
The announcement comes as Sanofi seeks to defend its No.2 spot in a global diabetes market worth over $40 billion, at a t…


20 years and $1.3B later, the first dengue vaccine approaches its watershed moment

20 years and $1.3B later, the first dengue vaccine approaches its watershed moment

July 11, 2014 7:34 am by | 0 Comments

PARIS (Reuters) – The first vaccine against dengue fever, from France’s Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help…


In clinical trials, injectable drug looks like a game-changer for people with chronic eczema

In clinical trials, injectable drug looks like a game-changer for people with chronic eczema

July 10, 2014 7:55 am by | 0 Comments

PARIS/NEW YORK (Reuters) – An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema…



Sanofi’s patent offensive against Eli Lilly targets rival insulin to Lantus

Sanofi’s patent offensive against Eli Lilly targets rival insulin to Lantus

July 8, 2014 3:21 pm by | 0 Comments

(Reuters) – Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and…


EU insulin market poised for a shakeup as panel backs Eli Lilly’s Lantus biosimilar

EU insulin market poised for a shakeup as panel backs Eli Lilly’s Lantus biosimilar

June 27, 2014 12:47 pm by | 0 Comments

LONDON (Reuters) – European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi SASY.PA whose top-selling Lantus is…


Sanofi, Regeneron antibody slows joint damage, improves symptoms in late-stage RA trial

Sanofi, Regeneron antibody slows joint damage, improves symptoms in late-stage RA trial

June 12, 2014 9:40 am by | 0 Comments

French Sanofi (EPA:SAN) and US Regeneron Pharmaceuticals (NASDAQ:REGN) unveiled today detailed positive findings from a Phase III study of sarilumab, a fully-human anti- IL-6R monoclonal antibody, in patients with active,…


Cialis could be available over the counter if Sanofi, Eli Lilly get their way

Cialis could be available over the counter if Sanofi, Eli Lilly get their way

May 28, 2014 10:59 am by | 0 Comments

PARIS (Reuters) – Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in…


UN agencies can now purchase Sanofi’s Shan5 pediatric vaccine

UN agencies can now purchase Sanofi’s Shan5 pediatric vaccine

May 5, 2014 4:41 pm by | 0 Comments

PARIS (Reuters) – French pharmaceutical company Sanofi said the World Health Organisation had given its Shan5 paediatric vaccine “prequalification status”, allowing the vaccine to be bought by United Nations agencies…



Glenmark receives $5 million milestone payment from Sanofi

Glenmark receives $5 million milestone payment from Sanofi

April 15, 2014 3:53 am by | 0 Comments

MUMBAI — Drug maker Glenmark Pharmaceuticals Ltd said on Tuesday that its new drug candidate for the treatment of autoimmune disorder has achieved another milestone towards final stage of discovery….


To spark cancer discoveries, several Big Pharma companies are sharing idle clinical trial data

To spark cancer discoveries, several Big Pharma companies are sharing idle clinical trial data

April 8, 2014 7:00 am by | 1 Comments

Big Pharma spends billions of dollars each year researching, developing and testing new treatments for cancer. In the meantime, it’s also collecting millions of data points that figuratively sit on…


Two guilty of insider trading in Sanofi deal

Two guilty of insider trading in Sanofi deal

March 8, 2014 4:07 am by | 0 Comments

A jury found two brothers guilty of using insider information to make an illicit $50,000 profit on the stock market in at least the eighth insider trading prosecution related to…


Sanofi sues Glenmark over generic filing on cardiac drug

Sanofi sues Glenmark over generic filing on cardiac drug

March 6, 2014 4:02 am by | 0 Comments

MUMBAI — Sanofi SA has sued Glenmark Pharmaceuticals Ltd in a US court after the Indian company filed an application with the US Food and Drug Administration (FDA) seeking marketing…


Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

February 10, 2014 12:16 pm by | 0 Comments

(Reuters) – U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi’s top-selling insulin treatment Lantus, increasing the long-term threat to the French company’s…


10 rival drug companies working together to find new drugs quicker

10 rival drug companies working together to find new drugs quicker

February 4, 2014 2:34 am by | 0 Comments

Feb 4 (Reuters) – Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal…


Sanofi buying percentage of Alnylam for $700 M to expand rare genetic disease drugs

Sanofi buying percentage of Alnylam for $700 M to expand rare genetic disease drugs

January 13, 2014 12:00 am by | 0 Comments

Jan 13 (Reuters) – French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop genetic disease drugs. The…


Sanofi plans to appeal U.S. rejection of its MS treatment Lemtrada

Sanofi plans to appeal U.S. rejection of its MS treatment Lemtrada

December 30, 2013 1:19 am by | 0 Comments

PARIS (Reuters) – Sanofi said its Lemtrada multiple sclerosis treatment failed to win approval from U.S. regulators to launch in the world’s biggest drug market.
The French firm said it planned to appeal the decision.
The Food and Drug Administration (…